| Kikkeri N Naresh, MD | |
|
825 Eastlake Ave E, Seattle, WA 98109-4405 | |
| (206) 520-5000 | |
| Not Available |
| Full Name | Kikkeri N Naresh |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 44 Years |
| Location | 825 Eastlake Ave E, Seattle, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396365300 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | TR61029384 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Washington Medical Ctr | Seattle, WA | Hospital |
| Harborview Medical Center | Seattle, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Association Of University Physicians | 0446162697 | 3009 |
News Archive
Alexion Pharmaceuticals, Inc. today announced that it has completed enrolling patients in all four previously announced prospective, open-label clinical studies investigating Soliris® (eculizumab) as a potential treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) being conducted in North America and multiple European countries.
According to Dr. Huisheng Ai's team, founder of Microtransplantation regimen mainly for Acute Myeloid Leukemia, over 700 patients have undergone this therapy since its emergence in 2002. Based at MST International Clinic for Leukemia in the 307th Hospital of Chinese People's Liberation Army in Beijing, about 40 hematology centers covering all main hospitals in 32 provinces of mainland China have adopted Microtransplantation regimen.
Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes.
OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress.
In a new study published on the bioRxiv* preprint server, scientists investigated several virological features of the Delta spike protein.
› Verified 1 days ago
| Entity Name | The Association Of University Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023041159 PECOS PAC ID: 0446162697 Enrollment ID: O20031105000244 |
News Archive
Alexion Pharmaceuticals, Inc. today announced that it has completed enrolling patients in all four previously announced prospective, open-label clinical studies investigating Soliris® (eculizumab) as a potential treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) being conducted in North America and multiple European countries.
According to Dr. Huisheng Ai's team, founder of Microtransplantation regimen mainly for Acute Myeloid Leukemia, over 700 patients have undergone this therapy since its emergence in 2002. Based at MST International Clinic for Leukemia in the 307th Hospital of Chinese People's Liberation Army in Beijing, about 40 hematology centers covering all main hospitals in 32 provinces of mainland China have adopted Microtransplantation regimen.
Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes.
OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress.
In a new study published on the bioRxiv* preprint server, scientists investigated several virological features of the Delta spike protein.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kikkeri N Naresh, MD Po Box 50095, Seattle, WA 98145-5095 Ph: (206) 520-5700 | Kikkeri N Naresh, MD 825 Eastlake Ave E, Seattle, WA 98109-4405 Ph: (206) 520-5000 |
News Archive
Alexion Pharmaceuticals, Inc. today announced that it has completed enrolling patients in all four previously announced prospective, open-label clinical studies investigating Soliris® (eculizumab) as a potential treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) being conducted in North America and multiple European countries.
According to Dr. Huisheng Ai's team, founder of Microtransplantation regimen mainly for Acute Myeloid Leukemia, over 700 patients have undergone this therapy since its emergence in 2002. Based at MST International Clinic for Leukemia in the 307th Hospital of Chinese People's Liberation Army in Beijing, about 40 hematology centers covering all main hospitals in 32 provinces of mainland China have adopted Microtransplantation regimen.
Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes.
OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress.
In a new study published on the bioRxiv* preprint server, scientists investigated several virological features of the Delta spike protein.
› Verified 1 days ago
Afshin Shameli, MD, PHD Pathology Medicare: Medicare Enrolled Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5000 | |
Dr. Mark Robert, Michael Kilgore, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, Box 356100, Seattle, WA 98195 Phone: 206-598-1821 Fax: 206-598-3803 | |
Corinne Lina Fligner, Pathology Medicare: Not Enrolled in Medicare Practice Location: University Of Washington Medical Ctr, 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-598-6400 | |
Jennifer Lapointe, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, C212, Box 356340, Seattle, WA 98195 Phone: 206-543-0065 | |
Lee-ching Zhu, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 125 16th Ave E, Seattle, WA 98112 Phone: 206-326-3000 | |
Dr. Saron Ann Elizabeth Smith, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1229 Madison St Ste 820, Seattle, WA 98104 Phone: 206-576-6507 | |
Mr. Ryuji Ohashi, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: Uwmc Pathology 1959 Ne Pacific, Box356100, Seattle, WA 98195 Phone: 206-598-7858 |